These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29255397)

  • 1. Human paraoxonase 2.
    Porntadavity S; Permpongpaiboon T; Sukketsiri W
    EXCLI J; 2010; 9():159-172. PubMed ID: 29255397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein.
    Ng CJ; Wadleigh DJ; Gangopadhyay A; Hama S; Grijalva VR; Navab M; Fogelman AM; Reddy ST
    J Biol Chem; 2001 Nov; 276(48):44444-9. PubMed ID: 11579088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraoxonase, a cardioprotective enzyme: continuing issues.
    Getz GS; Reardon CA
    Curr Opin Lipidol; 2004 Jun; 15(3):261-7. PubMed ID: 15166781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The paraoxonase 1, 2 and 3 in humans.
    Rajkovic MG; Rumora L; Barisic K
    Biochem Med (Zagreb); 2011; 21(2):122-30. PubMed ID: 22135851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Paraoxonase: The Universal Factor of Antioxidant Defense in Human Body].
    Borovkova EI; Antipova NV; Komeenko TV; Shakhparonov MI; Borovkov IM
    Vestn Ross Akad Med Nauk; 2017; 72(1):5-10. PubMed ID: 29308836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2.
    Ng CJ; Bourquard N; Grijalva V; Hama S; Shih DM; Navab M; Fogelman AM; Lusis AJ; Young S; Reddy ST
    J Biol Chem; 2006 Oct; 281(40):29491-500. PubMed ID: 16891303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: The role of paraoxonase in cardiovascular diseases.
    Kowalska K; Socha E; Milnerowicz H
    Ann Clin Lab Sci; 2015; 45(2):226-33. PubMed ID: 25887882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients.
    Leus FR; Zwart M; Kastelein JJ; Voorbij HA
    Atherosclerosis; 2001 Feb; 154(3):641-9. PubMed ID: 11257265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developmental expression of paraoxonase 2.
    Garrick JM; Dao K; de Laat R; Elsworth J; Cole TB; Marsillach J; Furlong CE; Costa LG
    Chem Biol Interact; 2016 Nov; 259(Pt B):168-174. PubMed ID: 27062895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraoxonase and atherosclerosis-related cardiovascular diseases.
    Chistiakov DA; Melnichenko AA; Orekhov AN; Bobryshev YV
    Biochimie; 2017 Jan; 132():19-27. PubMed ID: 27771368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of PON1 and PON2 in cardiovascular disease and innate immunity.
    Shih DM; Lusis AJ
    Curr Opin Lipidol; 2009 Aug; 20(4):288-92. PubMed ID: 19474728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraoxonases-1, -2 and -3: What are their functions?
    Furlong CE; Marsillach J; Jarvik GP; Costa LG
    Chem Biol Interact; 2016 Nov; 259(Pt B):51-62. PubMed ID: 27238723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraoxonase: Its antiatherogenic role in chronic renal failure.
    Prakash M; Phani NM; Kavya R; Supriya M
    Indian J Nephrol; 2010 Jan; 20(1):9-14. PubMed ID: 20535264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Paraoxonase-2 (PON2): Protein Functions and Modulation.
    Manco G; Porzio E; Carusone TM
    Antioxidants (Basel); 2021 Feb; 10(2):. PubMed ID: 33562328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice.
    Ng CJ; Hama SY; Bourquard N; Navab M; Reddy ST
    Mol Genet Metab; 2006 Dec; 89(4):368-73. PubMed ID: 16935014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences.
    Aviram M; Rosenblat M
    Curr Opin Lipidol; 2005 Aug; 16(4):393-9. PubMed ID: 15990587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression.
    Giordano G; Tait L; Furlong CE; Cole TB; Kavanagh TJ; Costa LG
    Free Radic Biol Med; 2013 May; 58():98-108. PubMed ID: 23376469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PON1 M/L55 mutation protects high-risk patients against coronary artery disease.
    Oliveira SA; Mansur AP; Ribeiro CC; Ramires JA; Annichino-Bizzacchi JM
    Int J Cardiol; 2004 Mar; 94(1):73-7. PubMed ID: 14996478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraoxonase genes and disease.
    Hegele RA
    Ann Med; 1999 Jun; 31(3):217-24. PubMed ID: 10442677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of paraoxonase in cancer.
    Bacchetti T; Ferretti G; Sahebkar A
    Semin Cancer Biol; 2019 Jun; 56():72-86. PubMed ID: 29170064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.